PL1631234T3 - Kompozycje i sposoby leczenia uszkodzeń OUN - Google Patents

Kompozycje i sposoby leczenia uszkodzeń OUN

Info

Publication number: PL1631234T3
Authority: PL; Poland
Prior art keywords: injury; functions; compositions; treatment; methods
Prior art date: 2003-05-16

Application number

PL04752310T

Other languages

English (en)

Inventor

Elliott A Gruskin

Anthony O Caggiano

Michael P Zimber

Andrew R Blight

Original Assignee

Acorda Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-16

Filing date

2004-05-17

Publication date

2012-02-29

2004-05-17 Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc

2012-02-29 Publication of PL1631234T3 publication Critical patent/PL1631234T3/pl

Links

230000006378 damage Effects 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title 1
102000004190 Enzymes Human genes 0.000 abstract 3
108090000790 Enzymes Proteins 0.000 abstract 3
230000000593 degrading effect Effects 0.000 abstract 3
208000034656 Contusions Diseases 0.000 abstract 2
229920002683 Glycosaminoglycan Polymers 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 2
210000003169 central nervous system Anatomy 0.000 abstract 2
230000009519 contusion Effects 0.000 abstract 2
208000014674 injury Diseases 0.000 abstract 2
238000011084 recovery Methods 0.000 abstract 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract 1
229920001287 Chondroitin sulfate Polymers 0.000 abstract 1
229920000045 Dermatan sulfate Polymers 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
230000037424 autonomic function Effects 0.000 abstract 1
229940059329 chondroitin sulfate Drugs 0.000 abstract 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
229940051593 dermatan sulfate Drugs 0.000 abstract 1
230000007659 motor function Effects 0.000 abstract 1
230000037152 sensory function Effects 0.000 abstract 1
208000020431 spinal cord injury Diseases 0.000 abstract 1
230000009529 traumatic brain injury Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Lubricants (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL04752310T 2003-05-16 2004-05-17 Kompozycje i sposoby leczenia uszkodzeń OUN PL1631234T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US47123603P	2003-05-16	2003-05-16
PCT/US2004/015253 WO2004103299A2 (en)	2003-05-16	2004-05-17	Compositions and methods for the treatment of cns injuries
EP04752310A EP1631234B1 (en)	2003-05-16	2004-05-17	Compositions and methods for the treatment of cns injuries

Publications (1)

Publication Number	Publication Date
PL1631234T3 true PL1631234T3 (pl)	2012-02-29

Family

ID=33476545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04752310T PL1631234T3 (pl)	2003-05-16	2004-05-17	Kompozycje i sposoby leczenia uszkodzeń OUN

Country Status (10)

Country	Link
US (3)	US20080025963A1 (pl)
EP (2)	EP1631234B1 (pl)
JP (2)	JP4754492B2 (pl)
AT (1)	ATE524067T1 (pl)
AU (1)	AU2004241088B2 (pl)
CA (1)	CA2525804C (pl)
ES (2)	ES2420510T3 (pl)
MX (1)	MXPA05012305A (pl)
PL (1)	PL1631234T3 (pl)
WO (1)	WO2004103299A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8183350B2 (en)	2002-05-04	2012-05-22	Acorda Therapeutics, Inc.	Compositions and methods for promoting neuronal outgrowth
EP3211084B1 (en)	2003-05-16	2019-03-27	Acorda Therapeutics, Inc.	Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en)	2003-05-16	2011-06-14	Acorda Therapeutics, Inc.	Methods of reducing extravasation of inflammatory cells
MXPA06013345A (es) *	2004-05-18	2008-10-31	Acorda Therapeutics Inc	Metodos para purificar condrointinasa y sus formulaciones estables.
JP2006232754A (ja) *	2005-02-25	2006-09-07	Gi Biopolis:Kk	消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
JP5189985B2 (ja)	2005-09-26	2013-04-24	アコーダセラピューティクス、インク．	コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
CA2663857C (en)	2006-09-20	2017-10-31	The Board Of Regents Of The University Of Texas System	Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
TW200817015A (en) *	2006-10-06	2008-04-16	Hen-Rich Cheng	A method for promoting axonal re-growth and behavior recovery in spinal cord injury
AU2016206267B2 (en) *	2006-10-10	2018-07-05	Acorda Therapeutics, Inc.	Compositions and methods of using chondroitinase abci mutants
CA3009034C (en)	2006-10-10	2020-08-18	Acorda Therapeutics, Inc.	Compositions and methods of using chondroitinase abci mutants
AU2014200000B2 (en) *	2006-10-10	2016-04-21	Acorda Therapeutics, Inc.	Compositions and methods of using chondroitinase abci mutants
WO2008149428A1 (ja) *	2007-06-05	2008-12-11	Glycoscience Laboratories, Inc.	自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
US20110059508A1 (en)	2007-06-29	2011-03-10	National University Corporation Nagoya University	Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
US8198083B1 (en)	2007-10-31	2012-06-12	William Gunter Loudon	Organotypic slices of the central nervous system
PL2244737T3 (pl)	2008-01-22	2020-05-18	The Board Of Regents Of The University Of Texas System	Kompozycje lotnego środka znieczulającego zawierające rozpuszczalniki ekstrakcyjne do znieczulania miejscowego i / albo zwalczania bólu
EP2286828B1 (en) *	2008-04-14	2016-05-18	National University Corporation Nagoya University	Improving agent for neuropathic pain
EP2153844A1 (en) *	2008-08-14	2010-02-17	HAUBECK, Hans-Dieter	Human hyaluronidases for axonal regrowth
WO2012136768A1 (en)	2011-04-08	2012-10-11	Hans-Dieter Haubeck	Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
EP3010524B1 (en)	2013-06-18	2019-12-25	University of Helsinki	Protamine in treatment of neuronal injuries
CN108795918A (zh) *	2018-07-18	2018-11-13	北京电子科技职业学院	一种外切型硫酸软骨素酶abc及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5270194A (en) *	1989-08-31	1993-12-14	Instrumentation Laboratory Spa	Stabilized glucose oxidase from Aspergillus Niger
US5804604A (en) *	1989-12-21	1998-09-08	Biogen, Inc.	Tat-derived transport polypeptides and fusion proteins
US5670617A (en) *	1989-12-21	1997-09-23	Biogen Inc	Nucleic acid conjugates of tat-derived transport polypeptides
US5679650A (en) *	1993-11-24	1997-10-21	Fukunaga; Atsuo F.	Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5262522A (en) *	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
US5496718A (en) *	1992-06-26	1996-03-05	Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation)	Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US7008783B1 (en) *	1992-09-22	2006-03-07	Maruha Corporation	Gene encoding chondroitinase ABC and uses therefor
US5578480A (en) *	1993-04-23	1996-11-26	American Cyanamid Company	Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US6248562B1 (en) *	1993-11-01	2001-06-19	Research Foundation State University Of New York	Chimeric proteins comprising borrelia polypeptides and uses therefor
US5498536A (en) *	1994-04-22	1996-03-12	American Cyanamid Company	Chondroitinase II from Proteus vulgaris
US6093563A (en) *	1994-07-08	2000-07-25	Ibex Technologies R And D, Inc.	Chondroitin lyase enzymes
US5997863A (en)	1994-07-08	1999-12-07	Ibex Technologies R And D, Inc.	Attenuation of wound healing processes
US6326166B1 (en) *	1995-12-29	2001-12-04	Massachusetts Institute Of Technology	Chimeric DNA-binding proteins
US5792743A (en)	1995-04-19	1998-08-11	Acorda Therapeutics	Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en)	1995-07-24	2001-11-06	The Scripps Research Institute	Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) *	1995-11-02	1999-02-09	Lockhead Martin Energy Research Corporation	Method for the production of dicarboxylic acids
WO1998046258A2 (en) *	1997-04-11	1998-10-22	Beth Israel Deaconess Medical Center, Inc.	Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
DE69829605T2 (de) *	1997-05-02	2006-02-09	Seikagaku Corp.	Chondroitinase enthaltende Zusammensetzungen
US6063378A (en) *	1997-08-22	2000-05-16	Seikagaku Corporation	Therapeutic agent for herniated intervertebral disc
US6153187A (en) *	1997-09-02	2000-11-28	Insight Strategy & Marketing Ltd.	Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
WO1999046368A2 (en) *	1998-03-13	1999-09-16	Biomarin Pharmaceuticals	Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6171575B1 (en) *	1998-04-06	2001-01-09	Shinichi Okuyama	Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
EP1109919A2 (en) *	1998-08-27	2001-06-27	Massachusetts Institute Of Technology	Rationally designed heparinases derived from heparinase i and ii
AU772479B2 (en) *	1998-10-06	2004-04-29	Stryker Corporation	Repair of larynx, trachea, and other fibrocartilaginous tissues
US5932563A (en) *	1998-10-23	1999-08-03	Ohio State Research Foundation	Methods for treating spinal cord injury
CA2393186A1 (en) *	1999-12-02	2001-06-07	Ibex Technologies, Inc.	Attenuation of fibroblast proliferation
WO2003000901A2 (en) *	2001-06-26	2003-01-03	Decode Genetics Ehf.	Nucleic acids encoding protein kinases
BR0211888A (pt) *	2001-08-13	2004-08-24	Univ Florida Res Foudantion In	Materiais e métodos para promoção de reparo de tecido nervoso
GB0205022D0 (en) *	2002-03-04	2002-04-17	Univ Cambridge Tech	Materials and methods for the treatment of cns damage
US8183350B2 (en) *	2002-05-04	2012-05-22	Acorda Therapeutics, Inc.	Compositions and methods for promoting neuronal outgrowth
CA2493509C (en) *	2002-06-03	2010-03-09	Massachusetts Institute Of Technology	Rationally designed polysaccharide lyases derived from chondroitinase b
US7163545B2 (en) *	2002-07-29	2007-01-16	Mayo Foundation For Medical Education And Research	Spinal cord surgical implant
US7074581B2 (en) *	2002-08-09	2006-07-11	Sysmex Corporation	Reagent for assaying lipid
ES2346868T3 (es) *	2002-08-10	2010-10-21	Yale University	Antagonistas de receptor nogo.
AU2003265561A1 (en) *	2002-08-15	2004-03-03	Acorda Therapeutics, Inc.	Chimeric protein
AU2003300012A1 (en) *	2002-12-30	2004-07-29	Indiana University Research & Technology Corporation	Method of treatment for central nervous system injury
US7959914B2 (en) *	2003-05-16	2011-06-14	Acorda Therapeutics, Inc.	Methods of reducing extravasation of inflammatory cells
EP3211084B1 (en) *	2003-05-16	2019-03-27	Acorda Therapeutics, Inc.	Proteoglycan degrading mutants for treatment of cns
US7507570B2 (en) *	2004-03-10	2009-03-24	Massachusetts Institute Of Technology	Recombinant chondroitinase ABC I and uses thereof
JP5189985B2 (ja) *	2005-09-26	2013-04-24	アコーダセラピューティクス、インク．	コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法

2004
- 2004-05-17 EP EP04752310A patent/EP1631234B1/en not_active Expired - Lifetime
- 2004-05-17 ES ES11152626T patent/ES2420510T3/es not_active Expired - Lifetime
- 2004-05-17 AU AU2004241088A patent/AU2004241088B2/en not_active Ceased
- 2004-05-17 MX MXPA05012305A patent/MXPA05012305A/es active IP Right Grant
- 2004-05-17 PL PL04752310T patent/PL1631234T3/pl unknown
- 2004-05-17 CA CA2525804A patent/CA2525804C/en not_active Expired - Fee Related
- 2004-05-17 US US10/847,540 patent/US20080025963A1/en not_active Abandoned
- 2004-05-17 AT AT04752310T patent/ATE524067T1/de not_active IP Right Cessation
- 2004-05-17 WO PCT/US2004/015253 patent/WO2004103299A2/en not_active Ceased
- 2004-05-17 JP JP2006533101A patent/JP4754492B2/ja not_active Expired - Fee Related
- 2004-05-17 ES ES04752310T patent/ES2373039T3/es not_active Expired - Lifetime
- 2004-05-17 EP EP11152626.5A patent/EP2353606B1/en not_active Expired - Lifetime
2010
- 2010-12-17 JP JP2010281092A patent/JP5432113B2/ja not_active Expired - Fee Related
2014
- 2014-01-30 US US14/169,063 patent/US20140248253A1/en not_active Abandoned
2019
- 2019-07-10 US US16/507,734 patent/US20200016247A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20140248253A1 (en)	2014-09-04
AU2004241088A1 (en)	2004-12-02
US20080025963A1 (en)	2008-01-31
JP2007520447A (ja)	2007-07-26
JP4754492B2 (ja)	2011-08-24
CA2525804A1 (en)	2004-12-02
WO2004103299A3 (en)	2008-01-24
WO2004103299A2 (en)	2004-12-02
JP5432113B2 (ja)	2014-03-05
ES2420510T3 (es)	2013-08-23
JP2011126880A (ja)	2011-06-30
AU2004241088B2 (en)	2010-08-05
ES2373039T3 (es)	2012-01-30
EP1631234A4 (en)	2008-11-19
EP2353606A2 (en)	2011-08-10
CA2525804C (en)	2017-04-25
EP1631234A2 (en)	2006-03-08
US20200016247A1 (en)	2020-01-16
EP1631234B1 (en)	2011-09-14
MXPA05012305A (es)	2006-04-18
WO2004103299A8 (en)	2005-03-31
ATE524067T1 (de)	2011-09-15
EP2353606B1 (en)	2013-04-17
EP2353606A3 (en)	2011-08-31

Publication	Publication Date	Title
PL1631234T3 (pl)	2012-02-29	Kompozycje i sposoby leczenia uszkodzeń OUN
AU2003273171A8 (en)	2005-11-03	Immunomodulatory compounds and methods of use thereof
ATE490786T1 (de)	2010-12-15	Behandlung von verletzungen des zentralen nervensystems
WO2005039504A3 (en)	2005-08-11	Compounds and methods for treating toll-like receptor 2-related diseases and conditions
WO2004060146A3 (en)	2005-03-17	Method of treatment for central nervous system injury
GB0300789D0 (en)	2003-02-12	Stimulation method for the sphenopalatine ganglia,sphenopalatine nerve,or vidian nerve for treatment of medical conditions
UA85055C2 (ru)	2008-12-25	Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2004022156A3 (en)	2004-08-05	Methods for treating central nervous system damage
WO2004028624A3 (en)	2004-04-29	Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2004019863A3 (en)	2004-06-24	Combination therapy for treatment of fibrotic disorders
MY118414A (en)	2004-10-30	Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
WO2005081619A3 (en)	2007-04-19	Compounds and methods for increasing neurogenesis
MX351062B (es)	2017-09-29	Proteinas de fusion para el tratamiento del snc.
WO2004028468A3 (en)	2004-10-21	Methods and compositions for treatment of neurological disorder
AU4363600A (en)	2000-11-10	Treatment of and/or prophylaxis against brain and spinal cord injury
AU2003304173A8 (en)	2005-01-04	Compositions and methods for promoting neuronal outgrowth
WO2005025502A3 (en)	2006-04-13	A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration
MX349462B (es)	2017-07-31	Composiciones y metodos para el tratamiento de lesiones del snc.
AP9901473A0 (en)	1999-03-31	Use of benzopyranols to treat neurological disorders.
IL130586A0 (en)	2000-06-01	IL6RIL6 chimera for the treatment of demyelinating diseases
AU8125801A (en)	2002-02-25	Method of treating neurodegenerative disorders of the retina and optic nerve head
HUP0002318A1 (hu)	2000-11-28	Eljárás idegregenerálódás serkentésére
AU2003301346A8 (en)	2004-05-04	Method of treating neurological diseases and disorders
AU2003233749A1 (en)	2003-10-27	Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system